TherapeuticsMD (TXMD) Cash & Equivalents (2010 - 2026)

TherapeuticsMD has reported Cash & Equivalents for 17 years, with the latest figure at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 46.54% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (up 46.54% YoY), and the FY2025 full-year result was $7.5 million, up 47.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $8.4 million, up from $7.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $49.3 million in Q4 2022, with the low at $4.3 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $14.4 million across 5 years, with a median of $7.5 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 91.23% — and 2025, when it surged 47.91%.
• TherapeuticsMD's Cash & Equivalents stood at $49.3 million in 2022, then sank by 91.23% to $4.3 million in 2023, then gained by 16.92% to $5.1 million in 2024, then surged by 47.91% to $7.5 million in 2025, then rose by 12.51% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q1 2026), $7.5 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.